196194-97-5

Basic information

• Product Name: N-(4-Methoxy-2-Methyl-5-nitrophenyl)acetaMide
• Synonyms: N-(4-Methoxy-2-Methyl-5-nitrophenyl)acetaMide
• CAS NO: 196194-97-5
• Molecular Formula: C₁₀H₁₂N₂O₄
• Molecular Weight: 224.21328
• Mol File: 196194-97-5.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 423.8±45.0 °C(Predicted)
• Appearance: /
• Density: 1.283±0.06 g/cm3(Predicted)
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• PKA: 13.62±0.70(Predicted)
• CAS DataBase Reference: N-(4-Methoxy-2-Methyl-5-nitrophenyl)acetaMide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(4-Methoxy-2-Methyl-5-nitrophenyl)acetaMide(196194-97-5)
• EPA Substance Registry System: N-(4-Methoxy-2-Methyl-5-nitrophenyl)acetaMide(196194-97-5)

Safety Data

• Hazardous Substances Data: 196194-97-5(Hazardous Substances Data)

Usage

General Description

N-(4-Methoxy-2-Methyl-5-nitrophenyl)acetaMide is a chemical compound with the molecular formula C10H12N2O4. It is a yellow solid, and it is commonly used as an intermediate in the synthesis of pharmaceutical drugs and organic compounds. N-(4-Methoxy-2-Methyl-5-nitrophenyl)acetaMide is known for its analgesic and anti-inflammatory properties, and it has been studied for its potential use in treating various medical conditions. Its structure contains a nitro group, a phenyl group, and an amide group, which give it its unique properties and make it a valuable ingredient in chemical reactions and drug development. Overall, N-(4-Methoxy-2-Methyl-5-nitrophenyl)acetaMide is an important chemical with diverse applications in the pharmaceutical and chemical industries.

Upstream product

• 31601-41-9 N-(4-methoxy-2-methylphenyl)acetamide 
• 7646-78-8 tin(IV) chloride 
• 102-50-1 2-methyl-4-methoxyaniline 

Downstream Products

• 1378949-53-1 methyl 2-acetamido-4-(2-acetamido-4-(2-acetamido-5-methoxy-4-nitrobenzamido)-5-methoxybenzamido)-5-methoxybenzoate 
• 1378949-50-8 methyl 2-acetamido-4-(2-acetamido-4-(2-amino-5-methoxy-4-nitrobenzamido)-5-methoxybenzamido)-5-methoxybenzoate hydrochloride 
• 1378949-48-4 methyl 2-acetamido-4-(2-acetamido-4-amino-5-methoxybenzamido)-5-methoxybenzoate 
• 1378949-47-3 methyl 2-acetamido-5-methoxy-4-(5-methoxy-4-nitro-2-(2-phenylacetamido)benzamido)benzoate 
• 1378949-46-2 methyl 2-acetamido-5-methoxy-4-(5-methoxy-2-(3-methylbutanamido)-4-nitrobenzamido)benzoate 
• 1378949-39-3 2-amino-5-methoxy-4-nitrobenzoic acid hydrochloride 
• 1378949-37-1 methyl 2-acetamido-4-amino-5-methoxybenzoate 
• 875155-09-2 methyl 2-acetamido-5-methoxy-4-nitrobenzoate 
• 196194-98-6 2-acetamido-5-methoxy-4-nitrobenzoic acid 
• 196194-99-7 2-amino-5-methoxy-4-nitrobenzoic acid 
• 5349-76-8 2,4-diamino-1-methoxy-5-methyl-benzene 
• 196195-00-3 6-methoxy-7-nitro-3,4-dihydroquinazolin-4-one 
• 854908-04-6 4-Amino-5-methyl-2-nitro-phenol 
• 123343-96-4 4-methoxy-2-methyl-5-nitroaniline 

Relevant articles and documents

Substituted quinolinone inhibitor

The invention provides a substituted quinolinone inhibitor and relates to a compound as shown in a formula (II) which is described in the specification or a pharmaceutically acceptable salt, solvate,active metabolite, polymorphic substance, ester, isomer or prodrug thereof, a pharmaceutical composition containing the compound as shown in the formula (II), and application of the compound and the pharmaceutical composition to treatment of diseases related to abnormal TOPK activity.

Double-sided α-helix mimetics

The design and synthesis of substituted bis- and tris-benzamides is reported in which the projection of side-chain residues on both sides of an α-helix is reproduced. The scaffold is conformationally constrained by a series of intramolecular hydrogen bonds, allowing for spatial and angular mimicry of the i, i+2, i+4 and i+6 side-chains in the case of the bis-benzamide, and may be extended to higher-order oligomers.

Quinazoline derivatives as VEGF inhibitors

The invention relates to quinazoline derivatives of formula (I) STR1wherein: Z represents --O--, --NH-- or --S--; m is an integer from 1 to 5; R 1 represents hydrogen, hydroxy, halogeno, nitro, trifluorometlyl, cyano, C 1-3 alkyl, C 1-3 alkoxy, C 1-3 alkylthio or NR 5 R 6 (wherein R 5 and R 6, which may be the same or different, each represents hydrogen or C 1-3 alkyl); R 2 represents hydrogen, hydroxy, halogeno, methoxy, amino, or nitro; R 3 represents hydroxy, halogeno, C 1-3 alkyl, C 1-3 alkoxy, C 1-3 alkanoyloxy, trifluoromethyl, cyano, amino or nitro; X 1 represents --O--, --CH 2 --, --S--, --SO--, SO 2 --, --NR 6 --, NR 8 CO--, --CONR 9 --SO 2 NR 10 -- or --NR 11 SO 2 --, (wherein R 7, R 8, R 9, R 10 and R 11 each represents C 1-3 alkyl, C 1-3 alkoxyC 2-3 alkyl); R 4 represents a group which is alkenyl, alkynyl or optionally substituted alkyl, which alkyl group may contain a heteroatom linking group, which alkenyl, alkynyl or alkyl group may carry a terminal optionally substituted 5 or 6 membered saturated carbocylic or heterocyclic group; and salts thereof, processes for their preparation, pharmaceutical compositions containing a compound of formula (I) or a pharmaceutically acceptable salt thereof as active ingredient the compounds of formula (I) and the pharmaceutically acceptable salts thereof inhibit the effects of VEGF, a property of value in the treatment of a number of disease states including cancer and rheumatoid arthritis.